Clinical Value of New Staging Systems for Multiple Myeloma

Purpose: We wanted to investigate the validity of the recently introduced Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) by comparing both systems with the widely accepted Durie/Salmon (DS) system for multiple myeloma patients. Materials and Methods: Between 1992 and 2005, 85 multiple myeloma patients (men: women 41:44, median age: 63 years (range: 36∼87)) with available baseline values of albumin and β2-microglobulin were enrolled. The clinical and laboratory data were retrospectively obtained. Results: According to the ISS, 11 patients were stage I (12.9%), 30 patients stage II (35.3%) and 44 patients stage III (51.8%). The median survivals of the ISS stages I, II and III were 78.6 months, 31.8 months and 15.1 months, respectively (p=0.015). The DS staging system was not able to predict the survival. For the SWOG staging system, 14 patients were stage I (16.4%), 27 patients stage II (31.8%), 27 patients stage III (31.8%) and 17 patients were stage IV (20.0%). The median survivals of the SWOG staging system stage I, II, III and IV were 78.6 months, 31.8 months, 11.6 months and 24.8 months, respectively (p=0.0075). Conclusion: The ISS staging system showed better reliability, simplicity and predictability for survival than the DS and SWOG staging systems for multiple myeloma patients. (Cancer Res Treat. 2007;39:171-174) KCI Citation Count: 0